Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy
Authors:
Open Access
- 1 March 2021
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 1743-1755
Abstract
Background: As a therapeutic target for cancer treatment, HSP90 has been explored extensively. However, the significant side effects of the HSP90 inhibitor 17AAG have limited its clinical use. Methods: In this study, we used hyaluronic acid (HA)–decorated DOTAP–PLGA hybrid nanoparticles (HA-DOTAP-PLGA NPs) as 17AAG-delivery carriers for targeted colon cancer therapy. Results: Different methods were used to characterize the successful fabrication of these hybrid PLGA NPs. Our results demonstrated that internalization of HA-NPs in colon cancer cells was governed by CD44receptor–mediated endocytosis. Annexin V–propidium iodide staining experiments revealed that cell apoptosis induced by HA-NPs-17AAG in colon cancer cells was more efficient than free 17AAG. In two animal models used to screen anticancer efficacy (Luc-HT29 subcutaneous xenograft and AOM/DSS-induced orthotopic tumor model), HA-NPs-17AAG significantly inhibited xenograft and orthotopic tumor growth, demonstrating HA-NPs-17AAG had much better therapeutic efficiency than free 17AAG. It is worth noting that great biocompatibility of HA-DOTAP-PLGA NPs was observed both in vitro and in vivo. Conclusion: Our research offers a preclinical proof of concept for colon cancer therapy with DOTAP-PLGA NPs as a creative drug-delivery system.Keywords
This publication has 34 references indexed in Scilit:
- Targeted Inhibition of Heat Shock Protein 90 Suppresses Tumor Necrosis Factor–α and Ameliorates Murine Intestinal InflammationInflammatory Bowel Diseases, 2014
- Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?Theranostics, 2014
- Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg functionMucosal Immunology, 2013
- Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake SelectionACS Nano, 2012
- To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug deliveryJournal of Controlled Release, 2010
- The role of heat shock proteins in gastrointestinal diseasesGut, 2009
- Applications of nanoparticles to diagnostics and therapeutics in colorectal cancerTrends in Biotechnology, 2007
- Clonogenic assay of cells in vitroNature Protocols, 2006
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences, 2006
- Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathwaysJournal of Cell Biology, 2001